Development of an icIEF assay for monitoring AAV capsid proteins and application to gene therapy products

被引:10
|
作者
He, Xiaoping Z. [1 ,2 ]
Powers, Thomas W. [1 ]
Huang, Sisi [1 ]
Liu, Zhenjiu [1 ]
Shi, Heliang [1 ]
Orlet, John D. [1 ]
Mo, Jim J. [1 ]
Srinivasan, Saipraveen [1 ]
Jacobs, Steven [1 ]
Zhang, Kun [1 ]
Runnels, Herbert A. [1 ]
Anderson, Melissa M. [1 ]
Lerch, Thomas F. [1 ]
机构
[1] Pfizer Inc, Analyt Res & Dev, Chesterfield, MO USA
[2] Pfizer Inc, Analyt Res & Dev, 875 Chesterfield Pkwy West, Chesterfield, MO 63017 USA
关键词
MONOCLONAL-ANTIBODIES; EXPRESSION; VECTORS; TROPISM;
D O I
10.1016/j.omtm.2023.03.002
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Adeno-associated virus (AAV) gene therapy vectors, which contain a DNA transgene packaged into a protein capsid, have shown tremendous therapeutic potential in recent years. Methods traditionally used in quality control labs, such as high-performance liquid chromatography (HPLC) and capil-lary electrophoresis (CE), do not provide a complete under-standing of capsid viral protein (VP) charge heterogeneity. In the present study, we developed simple, one-step sample prep-aration and charge-based VP separation using imaged capillary isoelectric focusing (icIEF) for monitoring AAV products. The robustness of the method was confirmed through a design of experiments (DoE) exercise. An orthogonal reverse-phase (RP) HPLC method coupled with mass spectrometry was devel-oped to separate and identify charge species. Additionally, capsid point mutants demonstrate the capability of the method to resolve deamidation at a single site on the viral proteins. Finally, case studies using two different AAV serotype vectors establish the icIEF method as stability indicating and demon-strate that increases in acidic species measured by icIEF corre-late with increased deamidation, which, we show, results in decreased transduction efficiency. The addition of a rapid and robust icIEF method to the AAV capsid analytical toolkit enables development and consistent manufacturing of well -characterized gene therapy products.
引用
收藏
页码:133 / 144
页数:12
相关论文
共 50 条
  • [41] Correlation of in vitro and in vivo biopotency assay for FIX AAV gene therapy vectors
    Lengler, J.
    Falkner, F. G.
    Ilk, R.
    Coulibaly, S.
    Hoellriegl, W.
    Gruber, B.
    Mayrhofer, J.
    Rottensteiner, H.
    Scheiflinger, F.
    HUMAN GENE THERAPY, 2017, 28 (12) : A22 - A22
  • [42] Development of an AAV5-Based Gene Therapy for Dyslipidemia
    Liu, Ying Poi
    MOLECULAR THERAPY, 2020, 28 (04) : 267 - 267
  • [43] Formulation Buffer Development for AAV8 Gene Therapy
    Tabish, Tanvir
    Fritscher, Eva
    Hasslacher, Meinhard
    Mittergradnegger, Dominik
    Fiedler, Christian
    MOLECULAR THERAPY, 2017, 25 (05) : 152 - 153
  • [44] Preclinical development of AAV-NPY gene therapy for epilepsy
    Patricio, Maria I.
    Barnard, Alun R.
    Green, Alexander L.
    During, Matthew J.
    Sen, Arjune
    MacLaren, Robert E.
    HUMAN GENE THERAPY, 2016, 27 (07) : A16 - A16
  • [45] Scalable rHSV Platform Development for AAV Gene Therapy Vectors
    Garg, Nitin
    Sharma, Saurabh
    Knop, David R.
    MOLECULAR THERAPY, 2019, 27 (04) : 159 - 159
  • [46] Intravenous administration of engineered AAV gene therapy capsid demonstrates improved CNS transduction in adult mice
    Murlidharan, G.
    Adachi, K.
    Wang, H.
    Nguyen, T.
    Johnson, B.
    Liu, L.
    Zhou, J.
    Felix-Ortiz, A.
    Christensen, E.
    Aubin, J.
    Goulet, M.
    Thompson, J.
    Carter, T.
    Hou, J.
    Sah, D.
    HUMAN GENE THERAPY, 2018, 29 (12) : A79 - A79
  • [47] Development of a Synthetic AAV Vector for Gene Therapy of Hemophilia in Children
    Shoti, Jakob
    Qing, Keyun
    Srivastava, Arun
    MOLECULAR THERAPY, 2022, 30 (04) : 332 - 332
  • [48] Development of AAV Gene Therapy for ECHS1 Deficiency
    Eller, Meghan M.
    Garza, Irvin
    Knight, Krishanna
    Bailey, Rachel M.
    MOLECULAR THERAPY, 2022, 30 (04) : 129 - 129
  • [49] Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors
    Tseng, Yu-Shan
    Agbandje-McKenna, Mavis
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [50] Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer
    Pipe, Steven
    Leebeek, Frank W. G.
    Ferreira, Valerie
    Sawyer, Eileen K.
    Pasi, John
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 15 : 170 - 178